ArticleJournal of medical imaging and radiation oncology2025
The FRED-X Flow Diverter-An Australian Experience.
Article in Journal of medical imaging and radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe FRED X flow diverter features antithrombotic surface treatment to reduce thrombogenicity. This study evaluated the safety and efficacy of FRED X in treating intracranial aneurysms in the Australian setting.
methodsClinical, procedural and imaging data were retrospectively reviewed for a consecutive series of patients at a single Australian neurovascular centre. Follow-up imaging was performed with a combination of MRA and IV-DSA imaging.
resultsA total of 39 consecutive patients (21% presenting with acute rupture) with 52 aneurysms treated with 40 FRED X devices between June 2021 and September 2024 were included in this study. Aneurysms were predominantly saccular (88%) and located in the ICA (82%), with a median size of 5.1 mm (IQR 2.4-8). Satisfactory wall apposition was achieved in 98% of cases. Additional coiling was performed in 20%, and balloon angioplasty in 5%. At a median follow-up of 28 weeks, complete aneurysm occlusion was achieved in 74% of cases, with adequate occlusion (> 90%) in 86%. Minor adverse events occurred in 10% and major adverse events in 5%. Overall mortality was 5%, exclusively in acute subarachnoid haemorrhage cases.
conclusionThe FRED X demonstrates favourable safety and efficacy profiles, with high technical success rates and satisfactory occlusion outcomes in an Australian setting. Thrombotic complications were rare, possibly reflecting the benefits of the antithrombotic coating, though larger studies with longer-term follow-up are needed for confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.